Detail akcie GSK ADS-WI online

Business Summary: GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, GSK plc (ADR) revenues increased 3% to L24.05B. Net income increased from L2.16B to L5.08B. Revenues reflect Europe segment increase of 11% to L5.47B, US segment increase of 3% to L12.42B. Net income benefited from Other segment loss decrease of 70% to L1.32B, Commercial Operations segment income increase of 4% to L12.54B, Unallocated segment loss decrease of 66% to L82M.